2,5mg/1 tab. (50 tabs.)
2,5mg/tab. (50 tabs.) of substance: letrozole, Letrozole Arenis Medico (Femara)
Out of stock
Letrobol contains 2.5mg of Letrozole.
Letrobol (Letrozole) is a non-steroidal selective third generation aromatase inhibitor used for the treatment of postmenopausal women with estrogen receptor-positive or estrogen receptor-unknown breast cancer.
Letrobol (Letrozole) is highly favored by athletes for its ability to mitigate the estrogenic side effects associated with the use of aromatizable anabolic/androgenic steroids, such as gynecomastia, fat buildup, and visible water retention.
Common side effects associated with the use of an aromatase inhibitor include hot flashes, joint pain, weakness, fatigue, mood changes, depression, high blood pressure, swelling of the arms/ legs, and headache.
Aromatase inhibitors may also decrease bone mineral density, which may lead to osteoporosis and an increase in fractures in susceptible patients.
Some individuals may also respond to the medication with gastrointestinal side effects including nausea and vomiting.
Aromatase inhibitors can harm the development of an unborn fetus, and should never be taken or handled during pregnancy.
When taken by men to reduce estrogenicity during prolonged periods of steroid treatment, aromatase inhibitors may increase cardiovascular disease (CVD) risk by retarding some beneficial properties of estrogen on cholesterol values. Studies have demonstrated that when an aromatizable steroid such as testosterone enanthate is taken in conjunction with an aromatase inhibitor, suppression of HDL (good) cholesterol levels become significantly more pronounced.
To mitigate the estrogenic effects of anabolic/androgenic steroid use, a daily dosage of 1.25-2.5mg administered once per day, without regard to meals. In some cases a dosage of a half of a tablet (1.25 mg) taken every other day is sufficient to prevent the onset of estrogenic side effects.